Ekaterinburg, Ekaterinburg, Russian Federation
Ekaterinburg, Ekaterinburg, Russian Federation
Yekaterinburg, Ekaterinburg, Russian Federation
Ekaterinburg, Ekaterinburg, Russian Federation
Subject. Drug-associated jaw osteonecrosis is a serious complication that can occur in patients receiving bisphosphonate therapy for bone metastases in malignant neoplasms. The studies are due to the widespread use of bisphosphonates in patients with proven bone metastases, with myeloma, and malignant neoplasms of various locations. Due to the toxic effects of bisphosphonates on soft tissues, the healing process is sluggish, often with a relapse. The task of finding optimal methods of stimulating local regenerative processes is urgent, since the use of general-action drugs can provoke continued growth of the primary tumor. The aim of the study was to develop a method for treating patients with a diagnosis of “drug-associated jaw osteonecrosis” using autologous plasma, which will further reduce the number of relapses and increase the effectiveness of treatment. Methodology. Patients with a diagnosis of “medically associated jaw osteonecrosis” underwent sequestrectomy with boundaries determined by perfusion by laser Doppler flowmetry, an APRF clot was placed on the bottom of the bone wound, and autologous plasma was injected into the wound edges in the postoperative period. Results. The result of applying this technique in the early postoperative period was a partial discrepancy of the edges of the wound, but the absence of sections of the exposed bone in the wound. After 6–8 weeks, we observed complete healing of the postoperative wound. The number of relapses was reduced from 16 to 3 (by 57.56 %). Conclusions. The use of autologous plasma in the treatment of drug-associated osteonecrosis is the most optimal way to stimulate local regenerative processes in the absence of the possibility of using general-action drugs.
bisphosphonate-related osteonecrosis of the jaw, osteomyelitis of the jaws, sequestrectomy, autoplasma
1. Vinogradova, N. G., Haritonova, M. P., Lvov, K. V. (2019). Lazernaya doplerovskaya floumetriya - metod opredeleniya granits sekvestrektomii pri bisfofonatnom osteonekroze [Laser doppler flowmetry as the method of sequestrectomy determination lines with bisphosphonate osteonecrosis of the jaw]. Ural'skiy meditsinskiy zhurnal [URAL MEDICAL JOURNAL], 3 (170), 101-105. (In Russ.)
2. Elovikova, T. M., Karaseva, V. V., Ermishina, E. Yu. et al. (2019). Opyt provedeniya professional'noy gigiyeny polosti rta u patsiyentov s khronicheskim parodontitom v sochetanii s medikamentozno assotsiirovannym osteonekrozom chelyusti [The expiriens resulting from the perfomance of professionsl oral cavity hygiene in patient whith a chronic periodontitis in combination whith a medication-associated osteonecrosis of the jaw]. Problemy stomatologii [Actual problems in dentistry], 15, 3, 28-33. (In Russ.)
3. Zhukova, N. A. (2016). Stadirovaniye bisfosfonatnogo osteonekroza chelyustey u bol'nykh zlokachestvennymi novoobrazovaniyami po dannym mul'tisrezovoy komp'yuternoy tomografii [Staging of Bisphosphonate-Related Osteonecrosis of the Jaws Inpatients with Malignant Tumors according multislice Computed Tomography]. Meditsinskaya Vizualizatsiya [Medical Visualization], 3, 17-24. (In Russ.)
4. Zhuravleva, M. V., Zhuravlev, L. V., Firsova, I. V. (2018). Sovremennyy vzglyad na problemu bifosfonatnogo osteonekroza chelyustey (obzornaya stat'ya) [Actual view on the problem of bisphosphonate related jaw osteonecrosis]. Zdorov'ye i obrazovaniye v XXI veke [Health and Education in the 21st Century], 5, 88-92. (In Russ.)
5. Zaslavskaya, N. A. (2014). Optimizatsiya profilaktiki i lecheniya bisfosfonatnykh osteonekrozov chelyustey u bol'nykh so zlokachestvennymi novoobrazovaniyami : diss. … kand. med. nauk [Optimization of the prevention and treatment of bisphosphonate osteonecrosis of the jaw in patients with malignant neoplasms : diss. ... cand. med. sciences]. Moscow, 167. (In Russ.)
6. Kerimova, K. M., Petrova, A. P. (2018). Bisfosfonatnyy osteonekroz chelyusti: Tekushcheye sostoyaniye problemy, rekomendatsii po profilaktike i taktike lecheniya [Bisphosphonate-related osteonecrosis of the jaw: the current status of the problem, recommendations for prevention and treatment tactics]. Mezhdunarodnyy Studencheskiy Nauchnyy Vestnik [International student research bulletin], 4, 152-155. (In Russ.)
7. Collective of authors. Association of Oncologists of Russia (2014). Klinicheskiye rekomendatsii po primeneniyu osteomodifitsiruyushchikh agentov u patsiyentov s metastazami v kosti zlokachestvennykh opukholey [Clinical recommendations for the use of osteomodifying agents in patients with malignant bone metastases]. Moscow, 6. (In Russ.)
8. Korotkich, N. N., Aralova, M. V., Ostroushko, A. P., Shipilova, V. V. (2017). Immuno-biologicheskoye obosnovaniye primeneniya obogashchennoy trombotsitami donorskoy plazmy dlya regional'nogo lecheniya ran [Immuno-biological substantiation of the use of platelet-rich donor plasma for regional treatment of wounds]. Vestnik eksperimental'noy i klinicheskoy khirurgii [Bulletin of Experimental and Clinical Surgery], 10, 2, 111-115. (In Russ.)
9. Medvedev, V. L., Opolskiy, A. M., Kogan, M. I. (2018). Perspektivy razvitiya regenerativnykh tekhnologiy. Sovremennyye znaniya ob autoplazme, obogashchennoy trombotsitami i vozmozhnosti yeyo primeneniya v lechenii urologicheskikh zabolevaniy [Prospects for the development of regenerative technologies. Current knowledge of platelet rich plasma and the possibility of its application in treatment of complicated urological deseases]. Kubanskiy nauchnyy meditsinskiy vestnik [Kuban Scientific Medical Bulletin], 25 (3), 155-161. (In Russ.)
10. Ovechkina, M. V. (2018). Densitometricheskaya otsenka plotnosti kostnoy tkani po dannym konusno-luchevoy tomografii pri primenenii in"yektsionnoy formy autologichnoy plazmy [Densitometric analysis of bone density using CBCT, in patients treated with injection form of autologous platelet plasma]. Paradontologiya [Periodontology], 23, 2, 67-70. (In Russ.)
11. Fomichev, E. V., Kirpichnikov, M. V., Podolsky, V. V. (2018). Bisfosfonatnyy osteonekroz, oslozhnennyy patologicheskim perelomom nizhney chelyusti [Bisphosphonate-related osteonecrosis of the jaw complicated by a pathological fracture of the mandible]. Volgogradskiy nauchno-meditsinskiy zhurnal [Volgograd Journal of Medical Research], 3 (59), 43-45. (In Russ.)
12. Shevtsova, V. V. (2018). Oslozhneniya i pobochnyye effekty lecheniya bisfosfonatami s tochki zreniya dokazatel'noy meditsiny [Adverse effects and complications of bisphosphonate therapy from the point of view of evidence-based medicine]. Okhrana materinstva i detstva [Maternal and Child Health Journal], 1 (31), 60-63. (In Russ.)
13. Aghaloo, T., Hazboun, R., Tetradis, S. (2015). Pathophysiology of Osteonecrosis of the Jaws. Oral Maxillofac Surg Clin North Am, 27 (4), 489-496. doi:https://doi.org/10.1016/j.coms.2015.06.001.
14. Al-Hamed, F., Mahri, M., Al-Waeli, H. et al. (2019). Regenerative Effect of Platelet Concentrates in Oral and Craniofacial Regeneration. Frontiers in Cardiovascular Medicine, 6, 126. doi.org/10.3389/fcvm.2019.00126
15. Bermúdez-Bejarano, E.-B., Serrera-Figallo, M.-Á., Gutiérrez-Corrales, A. et al. (2017). Analysis Of Different Therapeutic Protocols For Osteonecrosis Of The Jaw Associated With Oral And Intravenous Bisphosphonates. Med Oral Patol Oral Cir Bucal, 1, 22 (1), e43-57. DOI:https://doi.org/10.4317/medoral.21477
16. Beth-Tasdogan, N. H., Mayer, B., Hussein, H., Zolk, O. (2017). Interventions for managing medication-related osteonecrosis of the jaw. Cochrane Database of Systematic Reviews. doi.org/10.1002/14651858.CD012432.pub2
17. Edwards, B. J., Gounder, M., McKoy, J. M. et al. (2008). Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw. Lancet Oncol, 9 (12), 1166-1172. doi:https://doi.org/10.1016/S1470-2045(08)70305-X.
18. Endo, Y., Kumamoto, H., Nakamura, M., et al. (2017). Underlying Mechanisms and Therapeutic Strategies for Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ). Biol. Pharm. Bull, 40, 739-750. doi:https://doi.org/10.1248/bpb.b16-01020.
19. Fleisher, K., Kontio, R., Otto, S. (2016). Antiresorptive Drug-related Osteonecrosis of the Jaw (ARONJ) - a Guide to Research. AO Foundation, 76.
20. Ji-Youn, K., Hyun, C. S., Hyeon-Gun, J. (2019). Refractory healing after surgical therapy of osteonecrosis of the jaw: associated risk factors in aged patients. Clinical Interventions in Aging, 14, 797-804. doi.org/10.2147/CIA.S200455
21. Lopez-Jornet, P., Sanchez Perez, A., Amaral Mendes, R., Tobias, A. (2016). Medication-related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. J Craniomaxillofac Surg, 44 (8), 1067-1072. doi.org/10.1016/j.jcms.2016.05.004
22. Toro, L. F., de Mello-Neto, J. M., Ventura dos Santos, F. F. et al. (2019). Application of Autologous Platelet-Rich Plasma on Tooth Extraction Site Prevents Occurence of Medication-Related Osteonecrosis of the Jaws in Rats. SCIENTIFIC REPORTS, 9-22. DOI:https://doi.org/10.1038/s41598-018-37063-y
23. Mânea, H. C., Urechescu, H. C., Balica, N. C. et al. (2018). Bisphosphonates-induced osteonecrosis of the jaw - epidemiological, clinical and histopathological aspects. Rom J Morphol Embryol, 59 (3), 825-831. doi.org/10.1007/s12105-007-0033-2
24. Merigo, E., Oppici, A., Parlatore, A., et al. (2018). Platelet-Rich Plasma (PRP) Rinses for the Treatment of Non-Responding Oral Lichen Planus: A Case Report. Biomedicines, 6, 6 (1), 429-433. doi:https://doi.org/10.3390/biomedicines6010015.
25. Otto, S., Pautke, C., Van den Wyngaert, T. et al. (2018). Medication-related osteonecrosis of the jaw: Prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev, 69, 177-187. doi:https://doi.org/10.1016/j.oooo.2018.09.008
26. Poxleitner, Ph., Engelhardt, M., Schmelzeisen, R., Voss, P. (2017). The Prevention Of Medication-Related Osteonecrosis Of The Jaw. Deutsches Ärzteblatt International | Dtsch Arztebl Int, 114, 63-69. DOI:https://doi.org/10.3238/arztebl.2017.0063
